期刊文献+

不同抗血小板药物对冠心病患者的治疗效果比较 被引量:3

Therapeutic effect of oral antiplatelet drugs on patients with coronary heart disease
下载PDF
导出
摘要 目的探究不同抗血小板药物对冠心病患者的临床疗效。方法将2015年1月~2017年12月收治的136例冠心病患者,随机分组,对照组(氯吡格雷)、治疗组(普拉格雷),每组68例,对两组治疗效果进行分析和对比。结果治疗组治疗效果好于对照组(P <0.05),治疗组药物不良反应发生情况低于对照组(P <0.05)。结论普拉格雷对冠心病患者具有理想的临床治疗效果,并且药物安全性较高、药物起效加快、药效持久。 Objective To explore the clinical therapeutic effect of oral antiplatelet drugs on patients with coronary heart disease.Methods According to the clinical data of 136 patients with coronary heart disease treated in our hospital from January 2015 to December 2017,they were randomly divided into the control group(clopidogrel group)and the treatment group(prasugrel group),each group had 68 patients,and the therapeutic effects of two groups were compared.Results The therapeutic effect of the treatment group was better than that of the control group(P<0.05),and the adverse drug reactions of the treatment group were better than that of the control group(P<0.05).Conclusion Oral antiplatelet drugs have ideal clinical therapeutic effect on patients with coronary heart disease,and drug safety is high,drug onset is accelerated,lasting efficacy,can be promoted in the medical industry.
作者 周斐昊 ZHOU Fei-hao(Yiqi Hospital,Changchun 130000,China)
机构地区 一汽总医院
出处 《中国处方药》 2018年第12期89-90,共2页 Journal of China Prescription Drug
关键词 冠心病 普拉格雷 氯吡格雷 治疗效果究 Coronary heart disease Prasugral Clopidogrel Therapeutic effect
  • 相关文献

参考文献6

二级参考文献45

  • 1Collet JP, Cuisset T, Rang6 G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting[J]. N EnglJMed, 2012, 367(22): 2 100.
  • 2Collet JP, Werkum JW.Individualised antiplatelet therapy- is there a role for platelet function testing in routine clini- cal practice?[J]. European Cardiology Review, 2010, 6 (1):41.
  • 3Frelinger AL, Li Y, Linden MD, et al. Association of cy- clooxygenase-l-dependent and -independent platelet func- tion assays with adverse clinical outcomes in aspirin-treat- ed patients presenting for cardiac Catheterization[J]. Cir- culation,2009,120(25) :2 586.
  • 4Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin"re- sistance" and risk of cardiovascular morbidity: systematic review and meta-analysis[J]. BMJ, 2008 (7 637) : 195.
  • 5Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high- dose clopidogrel based on platelet function testing after per- cutaneous coronary intervention: the GRAVITAS random- ized trial[J]. JAMA, 2011, 305 (11) : 1 097.
  • 6Price MJ, Kalyanasundaram A, Berger PB, et al. The evi- dence base for platelet function testing in patients under- going percutaneous coronary intervention response to price[J]. Circ Cardiovasc lnterv, 2010, 3(3): 277.
  • 7Menozzi A, Lina D, Conte D, et al. Antiplatelet therapy in acute coronary syndromes[J]. Expert Opin Pharmacoth- er,2012, 13(1):27.
  • 8Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high plate- let reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Re- activity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasug- rel) study[J]. JAm Coil Cardiol,2012,59(24) :2 159.
  • 9Gurbel PA, Erlinge D, Ohrnan EM, et al.Platelet function during extended prasugrel and clopidogrel therapy for pa- tients with ACS treated without revascularization: the TRILOGY-ACS platelet function substudy[J]. JAMA, 2012,308(17) : 1 785.
  • 10Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/ SCAI 2005 guideline update for percutaneous coronary in- tervention-summary article: a report of the American Col- lege of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention) [J]. Circulation, 2006, 113 (1) : 156.

共引文献33

同被引文献54

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部